Annexon presented additional positive phase 3 results for anx005 c1q-targeted immunotherapy in guillain-barrÉ syndrome at the 2024 pns annual meeting

Anx005-treated patients demonstrated faster and more complete recovery from week 1 through week 26 on primary and multiple pre-specified endpoints

ANNX Ratings Summary

ANNX Quant Ranking